NCT06184750 2026-03-19
Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
Clinical Trials
9 trialsNCT05941520 2026-03-18
Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT04570956 2026-01-23
Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia, Lobular Carcinoma In Situ, or Increased Breast Cancer Risk
Mayo Clinic
Phase 2 Terminated
NCT06033092 2025-08-28
TOLERANT
European Institute of Oncology
Phase 2 Active not recruiting
NCT00096369 2019-01-24
Tamoxifen in Preventing Breast Cancer in Women at Increased Risk for Breast Cancer
University of Texas Southwestern Medical Center
Phase 2 Terminated
NCT00290654 2017-12-28
Internal Radiation Therapy After Lumpectomy in Treating Women With Ductal Carcinoma in Situ
Masonic Cancer Center, University of Minnesota
Phase 2 Terminated
NCT00764322 2017-08-01
NRR
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT00031720 2016-07-13
Soy Protein Supplement In Treating Hot Flashes in Postmenopausal Women Receiving Tamoxifen for Breast Disease
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00077168 2009-02-09
Adjuvant Radiation Therapy Compared With Observation After Surgery in Treating Women With Estrogen Receptor Positive or Progesterone Receptor Positive Ductal Carcinoma In Situ of the Breast Who Are Receiving Tamoxifen or Anastrozole
National Cancer Institute (NCI)
Phase 2 Unknown